Why Is BIONTECH SE ADR (BNTX) Stock Down Today?

Why BNTX stock is down today

BNTX stock closed down 8.55% at $101.88 after the company announced the termination of a Phase 2 clinical trial of its experimental colorectal cancer treatment, cevumeran. The decision followed a recommendation from an independent Data Safety Monitoring Board, which identified a numerical imbalance in overall survival between treatment arms. The stock opened at $111.42 but quickly declined, hitting a session low of $94.01 before closing near $100. The move overshadowed recent positive news regarding the FDA approval of the XFG-adapted 2026-2027 COVID-19 vaccine in collaboration with Pfizer.

What Happened

BioNTech announced the termination of its Phase 2 monotherapy trial of cevumeran in ctDNA-positive resected colorectal cancer patients. The Data Safety Monitoring Board (DSMB) advised the company to halt patient treatment and the trial due to a lack of efficacy, as the board identified a survival imbalance between the treatment and control arms. No new safety signals were reported. The company attributed the decision to the trial's design and the observed imbalance in outcomes. This news led to immediate sell pressure, with the stock dropping more than 9% at its low.

In contrast, BioNTech and Pfizer received FDA approval for the updated XFG-adapted 2026-2027 COVID-19 vaccine. The approval aligns with FDA guidance to better match circulating variants. However, this positive development did not offset the impact of the halted cancer trial on investor sentiment.

What The Data Shows

The stock opened at $111.42 and traded as high as $111.91 before falling sharply to $94.01, a decline of nearly 10%. The stock closed at $99.58, with 0.4 million shares traded, representing 0.4 times the 3-month average. The session volume was below average, indicating limited liquidity. The stock is currently trading within its 52-week range of $79.52 to $124.00. BioNTech remains unprofitable, with a trailing twelve-month EPS of -7.77 and a net margin of -63.6%. The stock has a beta of 1.28, indicating higher volatility than the market.

What To Watch

Investors should monitor BioNTech’s upcoming earnings date if provided. Otherwise, coverage breadth and further developments in its cancer and vaccine pipelines will be key to watch in the coming weeks.